The University of Cambridge Pancreatic Cancer Centre brings researchers in basic and clinical science together with surgeons, physicians and nurses who treat pancreatic cancer at Addenbrooke's Hospital, in a multi-disciplinary approach to translational research to improve patient outcomes.
Current open trials in Cambridge
The table below lists the current trials open in Cambridge for pancreatic, biliary tract and neuroendocrine cancers (last updated January 2016).
|Trial name||Trial description||Contact|
|APACT||Comparison of Gemcitabine/Abraxane combination to Gemcitabine alone as adjuvant therapy for patients who have undergone surgery for the removal of pancreatic cancer. Multi-centre international trial. Open to recruitment.||Dr Pippa Corrie|
|ESPAC-4||Comparison of gemcitabine-capecitabine chemotherapy combination to gemcitabine alone in patients who have undergone surgery for the removal of pancreatic cancer. Multi-centre trial. UKCRN ID 4307. Now open to ampullary patients only.||Dr Pippa Corrie|
|PRICKLE||Combination Gemcitabine/Abraxane in borderline locally advanced pancreatic cancer. Initiated in Cambridge. UKCRN ID 16739. Open to recruitment.||Dr Bristi Basu|
|PRICKLE Follow-up||Observational study of long-term outcomes of patients consented to PRICKLE||Dr Bristi Basu|
If you would like further information about how to take part in any of the clinical trials listed here that are open to recruitment, please talk to your cancer specialist as patients usually need to be referred by their doctor.
Cambridge Cancer Trials Centre contact for pancreatic, biliary tract and neuroendocrine cancer trials: Dr Bristi Basu